Phase 1 study of PRT13722 in patients with HR+ breast cancer anticipated to begin enrolling patients in the fourth quarter of 2026. WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company to proceed with a Phase 1 study under its Investigational New Drug Application (IND) for PRT13722, an oral KAT6A selective degrader being developed

Researchers have found a way to make cancer-killing immune cells more powerful and precise. By adding specific signaling components, they boosted the cells’ readiness to attack tumors. Surprisingly, briefly suppressing the cells with a drug before use made them even more effective later. The approach could help create safer, stronger next-gen cancer treatments.Researchers in Brazil are advancing a promising form of cancer immunotherapy by making natural killer (NK) cells more powerful and precis

Allschwil, Switzerland, September 14, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its partner Asahi Kasei Therapeutics Corp. started a phase 2 clinical study in Japan with the antifungal Cresemba® (isavuconazole) for pediatric patients at risk of deep mycoses. Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “We are ver

SHANGHAI and HONG KONG, Sept. 14, 2026 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that a preclinical research paper evaluating the combination of ATG-037 (CD73 Small Molecule Inhibitor) and selinexor

Johnson & Johnson's Rybrevant (amivantamab-vmjw) plus chemotherapy helped push median overall survival (OS) close to the three-year mark in previously untreated patients with advanced non–small-cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations, but the survival gain over chemotherapy alone fell short of statistical significance.The company nevertheless touted the finding as "the longest reported median OS in this patient population, which is nearly twice the historical median."T

Definium Therapeutics is reporting a second late-stage win for its LSD-based drug in generalised anxiety disorder (GAD), just over a month after unveiling positive results from the first of two Phase III studies in the condition.The company said Monday that its DT120 orally disintegrating tablet (ODT), an optimised formulation of lysergide, met the primary endpoint in the Phase III PANORAMA study, with the 100-µg dose producing a statistically significant improvement in anxiety symptoms versus p

Cellectis is halting work on its allogeneic CAR-T cell therapies to instead focus on early-stage in vivo editing programmes, the company announced Monday. The strategic shift, which will also see the company pivot from oncology to chronic disease, triggered a 41% drop in its shares. The biotech is now looking for partnership opportunities for lasme-cel and eti-cel, which it was developing for B-cell acute lymphoblastic leukaemia (B-ALL) and non-Hodgkin lymphoma (NHL)."Despite our continued convi

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has delivered a clear progression-free survival (PFS) advantage against Merck & Co.'s checkpoint inhibitor Keytruda (pembrolizumab) plus chemotherapy in first-line HER2-mutant non–small-cell lung cancer (NSCLC), but the initial overall survival (OS) readout seems to point in the opposite direction.Enhertu was granted accelerated approval in 2022 for second-line use based on Phase II data from the DESTINY-Lung02 trial, where it dem

Shennon Biotechnologies has welcomed a new chief executive and refreshed its cash reserves, both of which will help shepherd the company's transition from early R&D to clinical development.The biotech on Monday raised $12 million and appointed Cyril Konto as CEO, succeeding founder Li Sun, who will transition to president and chief technology officer. Konto previously served as the executive director for early immuno-oncology clinical development at Pfizer, and prior to that, was the director of

Having recently entered the lung cancer field via the FDA approval of its newly-acquired ROS1 selective inhibitor Jideytro (zidesamtinib), GSK is pushing forward with plans to expand use to include first-line treatment based on new data presented over the weekend at the World Conference on Lung Cancer (WCLC).Jideytro gained FDA clearance in July for adults with locally advanced or metastatic ROS1-positive non–small-cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor. The decision